First FDA approval of neoadjuvant therapy for breast cancer: Pertuzumab for the treatment of patients with HER2-positive breast cancer

Clinical Cancer Research

Volumn 20, Issue 21, 2014, Pages 5359-5364

  Amiri Kordestani, Laleh ^a   Wedam, Suparna ^a   Zhang, Lijun ^a   Tang, Shenghui ^a   Tilley, Amy ^a   Ibrahim, Amna ^a   Justice, Robert ^a   Pazdur, Richard ^a   Cortazar, Patricia ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; PERTUZUMAB; PLACEBO; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; CANCER STAGING; CARDIOTOXICITY; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FOOD AND DRUG ADMINISTRATION; HEART LEFT VENTRICLE FAILURE; HER2 POSITIVE BREAST CANCER; HUMAN; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ADJUVANT THERAPY; BREAST NEOPLASMS; GENETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED STATES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; HUMANS; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84909586316     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1268     Document Type: Article

References (13)

1. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 2013;382:1021-8.
2. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009:463-75.
3. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004;64:2343-6.
4. Blumenthal GM, Scher NS, Cortazar P, Chattopadhyay S, Tang S, Song P, et al. First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Clin Cancer Res 2013; 19:4911-6.
5. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-19.
6. Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013;14:461-71.
7. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25-32.
8. Prowell T, Cortazar P. Pathologic complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use of an endpoint to support accelerated approval [Internet]. Draft guidance for industry. Silver Spring (MD): FDA, Office of Hematology Oncology Products, Division of Oncology Products 1, Breast Oncology Group; 2012 May [cited 2014 Aug 18]. Report No.: FDA-2012-D-0432. Available from: http://www.fda.gov/Drugs/ucm309182.htm
9. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384:164-72.
10. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013;24:2278-84.
11. Drugs@FDA [database on the Internet]. Silver Spring (MD): FDA; 2013. [cited 2014 Aug 18]. Medical review; ID: 3379183; [about 104 p.]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2013/125409Orig1s051MedR.pdf Files updated daily
12. Drugs@FDA [database on the Internet]. Silver Spring (MD): FDA; 2013. [cited 2014 Aug 18]. Label; ID: 3384285; [about 24 p.]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125409s051lbl.pdf Files updated daily.
13. Montemurro F, Di Cosimo S, Arpino G. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Ann Oncol 2013;24:2715-24.